Researcher
Julio Rosenstock, MD
Biography & Research Background
Julio Rosenstock, MD, is a clinical researcher affiliated with Velocity Clinical Research at Medical City (Dallas, TX, USA) and a widely published expert in incretin-based pharmacology research. He is the lead author of a 2023 publication in The Lancet on retatrutide (LY3437943), a GIP, GLP-1 and glucagon receptor agonist, and has authored hundreds of peer-reviewed publications on incretin and glucagon receptor biology. Julio Rosenstock is being referenced as one of the leading scientists involved in retatrutide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this doctor.
External Profiles
Authored Research Profiles (1)
Julio Rosenstock, MD is referenced as a leading researcher in the following peptide research profiles on SHR3D Aminos:
Disclaimer
Julio Rosenstock, MD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.